FDA 483 - Sun Pharmaceutical Industries Ltd. - June 13, 2025

Sun Pharmaceutical Industries Ltd., located in Halol, Gujarat, India, underwent an FDA inspection from June 2 to June 13, 2025. The inspection revealed significant violations concerning the prevention of microbiological contamination in sterile drug products. Key issues included inadequate aseptic procedures and poor environmental monitoring, which were repeat observations from a previous warning letter issued in December 2022.

Specific violations observed during the inspection included improper handling and disinfection of equipment and materials within sterile environments. For instance, operators were observed transferring items into sterile areas without proper disinfection, and there were instances of personnel reaching over open sterile containers, risking contamination. Additionally, space constraints led to compromised aseptic techniques, such as operators having to reach over sterile areas, and inadequate airflow studies for exposed materials.

The regulatory framework requires drug manufacturers to adhere to stringent aseptic processing standards to ensure product sterility. The FDA's observations indicate non-compliance with these standards, necessitating immediate corrective actions. Sun Pharmaceutical Industries Ltd. is expected to address these deficiencies by revising their aseptic procedures, enhancing environmental monitoring, and ensuring adequate personnel training to prevent future occurrences. The company is encouraged to discuss any objections or corrective actions with the FDA or submit detailed plans to rectify the identified issues.